The Europe cancer biomarker market is estimated to rise with a CAGR of 10.83% over the forecasting years 2019-2027. Europe is witnessing significant growth due to technological developments. Also, The growth of the market is highly attributed to the rising incidence of cancer and the growing senior population. These are also an important driver for the growth of the overall healthcare industry in the region.

EUROPE CANCER BIOMARKER MARKET FORECAST 2019-2027

Europe Cancer Biomarker Market by Profiling Technology (Omic Technology (Genomics, Proteomics, Other Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetic-based Tests) by Biomaker Genetic Biomarkers, Protein Biomarkers, Glyco Biomarkers) by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others Cancer Type) by Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Other Application) & by Geography

Request free sample

Report Summary

The United Kingdom, Germany, Spain, Italy, France and rest of Europe are the prime countries analyzed for this region. The rising number of cancer cases and the encouragement by the FDA for biomarker research and development are aiding the growth for the European market. Some of the consortiums/associations in the Cancer biomarker market in Europe are European Association for Cancer Research, German Consortium for Translational Cancer Research and European Society for Breast Cancer Specialist.

Major European companies have collaborated with other companies to accelerate the process of R&D activities and product development. For instance, GlaxoSmithKline plc has collaborated with Adaptimmune Therapeutics plc to boost the development of Adaptimmune’s lead T-cell therapy to treat cancer.

Some of the noted market players in this region include Becton Dickinson and Company, Agendia N.V., Qiagen N.V., Aureon Biosciences, Inc., Diadexus Inc. (Acquired By Diazyme Laboratories), Agilent Technologies, Inc., Astellas Pharma Inc., Clarient, Inc. (Acquired By Neogenomics Laboratories), Beckman Coulter, Bristol-Myers Squibb, Sanofi, Celgene Corporation, Illumina, Inc., Abbott Laboratories and Roche Diagnostics Ltd.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
RESEARCH METHODOLOGY
- SOURCES OF DATA
  - SECONDARY DATA
  - PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
  - OMIC TECHNOLOGY GENERATED THE HIGHEST REVENUE IN TERMS OF PROFILING TECHNOLOGY
  - GLYCO BIOMARKERS ARE THE FASTEST GROWING CANCER BIOMARKERS
  - BREAST CANCER HOLDS THE LARGEST MARKET SHARE IN TERMS OF CANCER TYPE
  - DIAGNOSTICS APPLICATION IS THE MAJORLY USED CANCER BIOMARKER APPLICATION

MARKET DYNAMICS
- MARKET SCOPE & DEFINITION
- MARKET DRIVERS
  - GROWING PREVALENCE ON RESEARCH OF CANCER BIOMARKERS
  - ENCOURAGEMENT FOR BIOMARKER DEVELOPMENT BY FDA
  - IMPROVED PRECISION AND SPEED OF DIAGNOSIS
  - HIGH INVESTMENT THROUGH GOVERNMENT AND PRIVATE FUNDS IN CANCER RELATED RESEARCH
  - DEVELOPMENT OF HIGHLY SPECIFIC DRUGS
  - GROWTH IN IMPORTANCE OF BIOLOGICAL AND TARGETED DRUG THERAPIES
  - TECHNOLOGICAL ADVANCEMENTS
  - GROWING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
- MARKET RESTRAINTS
  - POOR COMPENSATION STRUCTURES
  - LOW ESTIMATED RATE OF SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS
  - TECHNICAL ISSUES RELATED TO CANCER BIOMARKERS
  - HIGH COST OF DRUG DEVELOPMENT
  - UNCLEAR GOVERNMENT REGULATION AND REIMBURSEMENT POLICIES
- MARKET OPPORTUNITIES
  - WIDE OPPORTUNITY TO GROW IN PERSONALIZED MEDICATION
  - SUPPORTS ON BIOMARKERS TEST
  - GROWING NUMBER OF CANCER PATIENTS AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES
  - ADVANCEMENT OF CANCER DRUGS RESEARCH
- MARKET CHALLENGES
  - LACKING ACCEPTANCE OF THE CANCER BIOMARKER
  - UNFAVORABLE COMPENSATION SITUATION
  - HIGH COST OF DEVELOPING COMPANION DIAGNOSTICS
  - RIGOROUS REGULATORY AGENDA
  - DEARTH OF SKILFUL WORKERS

MARKET BY PROFILING TECHNOLOGY
- OMIC TECHNOLOGY
- IMAGING TECHNOLOGIES
- IMMUNOASSAYS
- CYTOGENETIC-BASED TESTS
MARKET BY BIOMARKER
- GENETIC BIOMARKERS
- PROTEIN BIOMARKERS
- GLYCO BIOMARKERS
MARKET BY CANCER TYPE
- LUNG CANCER
- BREAST CANCER
- COLORECTAL CANCER
- PROSTATE CANCER
- STOMACH CANCER
- OTHERS CANCER TYPE
MARKET BY APPLICATION
- DIAGNOSTICS
- DRUG DISCOVERY AND DEVELOPMENT
- PROGNOSTICS
- RISK ASSESSMENT
- OTHER APPLICATION
KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
  - THREAT OF NEW ENTRANTS
  - THREAT OF SUBSTITUTE PRODUCT
  - BARGAINING POWER OF BUYER
  - BARGAINING POWER OF SUPPLIERS
  - INTENSITY OF COMPETITIVE RIVALRY
- KEY BUYING CRITERIA
  - PRICING
  - EFFICACY
  - APPLICATION AND EFFECTIVENESS
- PATENT ANALYSIS
- ONCOLOGY DRUGS APPROVALS BY THE FDA
- OPPORTUNITY MATRIX
GEOGRAPHICAL ANALYSIS
- EUROPE
  - GERMANY
  - THE UNITED KINGDOM
  - FRANCE
  - ITALY
  - SPAIN
  - REST OF EUROPE

COMPETITIVE LANDSCAPE
- MARKET SHARE ANALYSIS
- COMPANY PROFILES
  - ABBOTT LABORATORIES
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - AGENDIA N.V.
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - AGILENT TECHNOLOGIES, INC.
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - AUREON BIOSCIENCES, INC
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - ASTELLAS PHARMA INC.
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - BECKMAN COULTER
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - BECTON DICKINSON AND COMPANY
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - BRISTOL-MYERS SQUIBB
    - COMPANY PROFILES
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - CELGENE CORPORATION
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - ILLUMINA, INC.
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - ROCHE DIAGNOSTICS LTD
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES
  - SANOFI
    - COMPANY OVERVIEW
    - PRODUCTS PORTFOLIO
    - SWOT ANALYSIS
    - STRATEGIC INITIATIVES
  - QIAGEN N.V.
    - COMPANY OVERVIEW
    - PRODUCT PORTFOLIO
    - SCOT ANALYSIS
    - STRATEGIC INITIATIVES

TABLE LIST

TABLE 1 EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

TABLE 2 RECENT RESEARCH ON BIOMARKERS

TABLE 3 LIST OF FDA APPROVED PROTEIN CANCER BIOMARKERS

TABLE 4 POTENTIAL CLINICAL USE OF CANCER BIOMARKERS

TABLE 5 MEDICAL TOURISM PRICES IN US DOLLAR

TABLE 6 EUROPE CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)

TABLE 7 EUROPE OMIC TECHNOLOGY MARKET 2019-2027 ($ MILLION)

TABLE 8 EUROPE IMAGING TECHNOLOGIES MARKET 2019-2027 ($ MILLION)

TABLE 9 EUROPE IMMUNOASSAYS MARKET 2019-2027 ($ MILLION)

TABLE 10 EUROPE CYTOGENETICS-BASED TESTS MARKET 2019-2027 ($ MILLION)

TABLE 11 EUROPE CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)

TABLE 12 EUROPE GENETIC BIOMARKERS MARKET 2019-2027 ($ MILLION)

TABLE 13 EUROPE PROTEIN BIOMARKERS MARKET 2019-2027 ($ MILLION)

TABLE 14 EUROPE GLYCO BIOMARKERS MARKET 2019-2027 ($ MILLION)

TABLE 15 EUROPE CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)

TABLE 16 EUROPE LUNG CANCER MARKET 2019-2027 ($ MILLION)

TABLE 17 EUROPE BREAST CANCER MARKET 2019-2027 ($ MILLION)

TABLE 18 EUROPE COLORECTAL CANCER MARKET 2019-2027 ($ MILLION)

TABLE 19 EUROPE PROSTATE CANCER MARKET 2019-2027 ($ MILLION)

TABLE 20 EUROPE STOMACH CANCER MARKET 2019-2027 ($ MILLION)

TABLE 21 EUROPE OTHERS CANCER TYPE MARKET 2019-2027 ($ MILLION)

TABLE 22 EUROPE CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)

TABLE 23 EUROPE DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

TABLE 24 EUROPE DRUG DISCOVERY AND DEVELOPMENT MARKET 2019-2027 ($ MILLION)

TABLE 25 EUROPE PROGNOSTICS MARKET 2019-2027 ($ MILLION)

TABLE 26 EUROPE RISK ASSESSMENT MARKET 2019-2027 ($ MILLION)

TABLE 27 EUROPE OTHER APPLICATION MARKET 2019-2027 ($ MILLION)

TABLE 28 PATENT PRODUCTS WITH THE EXPIRY DATE

TABLE 29 PATENT PUBLICATIONS RELATED TO BREAST CANCER 2017

TABLE 30 PATENT PUBLICATIONS RELATED TO PROSTATE CANCER 2017

TABLE 31 PATENT PUBLICATIONS RELATED TO LUNG CANCER 2017

TABLE 32 EUROPE CANCER BIOMARKER MARKET BY COUNTRY 2018-2026 ($ MILLION)

FIGURES LIST

FIGURE 1 EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE 2 PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING

FIGURE 3 PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)

FIGURE 4 EUROPE CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)

FIGURE 5 EUROPE CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)

FIGURE 6 EUROPE CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)

FIGURE 7 EUROPE CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)

FIGURE 8 PORTER’S FIVE FORCE ANALYSIS

FIGURE 9 EUROPE CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)

FIGURE 10 GERMANY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE 11 THE UNITED KINGDOM CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE 12 FRANCE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE 13 ITALY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE 14 SPAIN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE 15 REST OF EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE 16 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

Segmentation

GEOGRAPHICAL ANALYSIS
- EUROPE
  - GERMANY
  - THE UNITED KINGDOM
  - FRANCE
  - ITALY
  - SPAIN
  - REST OF EUROPE

MARKET BY PROFILING TECHNOLOGY
- OMIC TECHNOLOGY
- IMAGING TECHNOLOGIES
- IMMUNOASSAYS
- CYTOGENETIC-BASED TESTS
MARKET BY BIOMARKER
- GENETIC BIOMARKERS
- PROTEIN BIOMARKERS
- GLYCO BIOMARKERS
MARKET BY CANCER TYPE
- LUNG CANCER
- BREAST CANCER
- COLORECTAL CANCER
- PROSTATE CANCER
- STOMACH CANCER
- OTHERS CANCER TYPE
MARKET BY APPLICATION
- DIAGNOSTICS
- DRUG DISCOVERY AND DEVELOPMENT
- PROGNOSTICS
- RISK ASSESSMENT
- OTHER APPLICATION